Advanced Biomed’s ADVB Stock Soars 26% After IPO and NMPA Clearance

ADVANCED BIOMED INC Overview

Advanced Biomed Inc. (NASDAQ: ADVB) is a biotechnology company headquartered in Tainan, Taiwan, focused on the research, development, and manufacturing of microfluidic biochip technologies for precision oncology. Established in 2014, the company’s platform integrates chip design, automated sample preparation, and single-cell analysis to enable early cancer screening, diagnosis, staging, and treatment monitoring through the detection of circulating tumor cells (CTCs).

Corporate Structure and Experience

Since its founding in 2014, Advanced Biomed has assembled interdisciplinary teams in Taiwan that include bioengineers, clinical scientists, and manufacturing specialists. While exact employee numbers are not publicly disclosed, the company has expanded its research and development and production capabilities to support multiple product lines and is preparing for the establishment of operational centers in North America and Europe. Its primary operations remain based in Taiwan, with an expansion focus in China.

Microfluidic diagnostics by beuwy.com Alexander Pütter

Developments and Milestones

• March 6, 2025: Advanced Biomed’s 1,640,000 shares of common stock began trading on the Nasdaq Capital Market at $4.00 per share under the ticker symbol ADVB.
• March 7, 2025: The company closed its initial public offering (IPO), raising US$6.56 million in gross proceeds and granting underwriters a 45-day option to purchase an additional 246,000 shares.
• Performance Verification: Pre-mass production trials indicated a 94% recovery rate for the A+Pre chip and a 79.5% recovery rate for the AC-1000 device, which met internal performance benchmarks.
• Regulatory Clearance: Both the A+Pre and AC-1000 systems have received clearance from China’s National Medical Products Administration (NMPA).
• Manufacturing Collaborations: Technology transfer agreements have been executed with Riva and Unimold to scale up production of microfluidic chips.
• Mid-2025 Plans: The company plans to initiate clinical research for the A+LCGuard lung cancer screening kit, aimed at differentiating benign from malignant pulmonary nodules.

Financial and Strategic Analysis

As of August 5, 2025, ADVB shares closed at US$0.5483, reflecting a 26.34% increase on trading volume of 817,891 shares on Nasdaq (NAS). Proceeds from the IPO are allocated to:

1. In vitro diagnostics (IVD) clinical research, chip design, and facility upgrades
2. Marketing and sales expansion
3. General working capital

Underwriter Craft Capital Management LLC led the firm-commitment offering under a registration statement declared effective by the SEC on February 11, 2025. The over-allotment option remains exercisable through April 21, 2025.

Market Position and Industry Context

Advanced Biomed operates in the liquid biopsy and microfluidic diagnostics sector, which includes multi-cancer early detection tests based on circulating tumor DNA (ctDNA) and intact CTC capture. The company employs a semiconductor-based, antigen-independent approach, providing an alternative to conventional antibody-based techniques. Its devices, such as the A+Pre and AC-1000, serve as complementary tools to emerging tests like Grail’s Galleri and Labcorp’s Plasma Complete. The company is advancing its regulatory pathways for market entry in North America and Europe, aiming to meet global demand for effective cancer diagnostic solutions.

tl;dr

On March 6–7, 2025, Advanced Biomed Inc. completed an IPO on Nasdaq, raising $6.56 million at $4 per share (ADVB). As of August 5, 2025, shares have traded at $0.5483 (up 26.34%), with 817,891 shares changing hands. The company has received NMPA clearance for its A+Pre and AC-1000 microfluidic platforms, demonstrated recovery rates of 94% and 79.5% in production trials, and entered manufacturing partnerships. Clinical research for the A+LCGuard lung cancer screening kit is slated to begin in mid-2025, as Advanced Biomed works toward market expansion in North America and Europe.